Wessel Doué F instruction manual
- Wessel Doué F instruction manual
- Pharmacological properties
- Indications for use
- Dosing and Administration
- Side effect
- Drug Interactions
- special instructions
- Leave conditions
- Storage conditions
- Shelf life
- The average price in pharmacies in Moscow
- Wessel Doué F Analogues
ATX code B01AB11
Pharmacotherapeutic group : anticoagulants.
Dosage form : capsules, solution for intravenous and intramuscular injections.
Product : soft oval gelatin capsules of brick-red color, containing a suspension of white-gray, pink or pink-cream color, a blister, a pack of cardboard;
Transparent yellow or light yellow solution, ampoules, contour cell packaging, cardboard box.
An anticoagulant drug of direct action. This drug is a natural product extracted from the small intestine of a domestic pig. Presented as a mixture of dermatan sulfate, heparin-like fraction and glycosaminoglycans. The mechanism of action of anticoagulant is due to the affinity of the fast-acting heparin fraction to antithrombin III, and dermatane to heparin cofactor II.
Active substance :
- Sulodexide (250 le (capsules) 600 le (solution for injection).
Auxiliary components :
Capsules: colloidal silicon dioxide, triglycerides, sodium lauryl sarcosinate. Gelatin shell: glycerol, gelatin, titanium dioxide, sodium ethylparaoxybenzoate, sodium propyl parabensobenzoate, iron oxide red.
Injection solution : sodium chloride, water for injection.
Anticoagulant properties of the drug are manifested due to its affinity for cofactor II heparin, inactivating thrombin. The mechanism of antithrombotic action is explained by the suppression of the activated X factor, increased synthesis and secretion of PGI 2, and a decrease in plasma levels of fibrinogen.
The prophylenolitic effect of anticoagulant is due to an increase in the level of the plasminogen activator and a decrease in the amount of its inhibitor in the blood.
With the restoration of the functional and structural integrity of the vascular endothelium and the restoration of the density of the negative electrical charge of the porbasal membrane, the angioprotective action of the drug is associated. At the same time, Vesel Douay F, by stimulating lipoprotein lipase, hydrolyzing triglycerides in the LDL, normalizes the rheological properties of the blood.
The effectiveness of anticoagulant in diabetic nephropathy is determined by the ability of the active ingredient, through the proliferation of mesangium cells, to reduce the production of the extracellular matrix and the thickness of the basal membrane.
About 90% of the sulodexide is adsorbed in the cells of the vascular endothelium. Here its concentration is 20-30 times higher than the concentration in other tissues. Absorption occurs in the small intestine.
Metabolized Vesel Douche F in the kidney and liver and is excreted 4 hours after application. The active ingredient is not desulfurized. As a consequence, there is no decrease in its antithrombotic activity and elimination from the organism does not accelerate.
At the end of 24 hours after intravenous administration of the drug, its secretion with urine is 50%, and after 2 days - 67%.
Indications for use
- Angiopathy, characterized by a high risk of thrombosis (including after a previous myocardial infarction);
- Deep vein thrombosis;
- Violation of cerebral circulation;
- Thrombophilic conditions;
- Microangiopathy of different genesis;
- Antiphospholipid syndrome;
- Heparin-induced thrombotic thrombocytopenia.
- Individual intolerance to the components of the drug;
- Pathological conditions accompanied by reduced blood coagulability;
- Hemorrhagic diathesis;
- I trimester of pregnancy.
Dosing and Administration
Injection solution for intramuscular or intravenous administration.
1 ampoule of the drug is administered daily, intravenously or intramuscularly, for 15-20 days. With bolus or drop administration, the anticoagulant is first dissolved in 150-200 ml of physiological solution.
It is recommended to take Vesel Douai F capsules within the next 30-40 days (1 capsule twice a day, between meals). The course of treatment is appointed twice a year. Dosing regimen can be changed by the attending physician. Of course, at the same time, the results of a clinical diagnostic examination should be taken into account.
From the side of the digestive tract : pain in the epigastric region, nausea, vomiting.
From the skin : itching, hives , skin rashes of various locations.
Other disorders : burning, soreness and the formation of a hematoma at the site of injection of the drug.
With simultaneous use of anticoagulant with other drugs, significant interaction of the components is not established. It is not recommended, with Vesel Douai F, to use drugs that affect the hemostatic system as direct and indirect anticoagulants and antiplatelet agents.
The drug should be administered under the control of the coagulogram. Before and at the conclusion of treatment it is necessary to determine the time of coagulation and bleeding, antithrombin II and activated partial thromboplatinum time (with the use of the drug, the last index is increased by 1.5 times). Vesel Douai F does not affect the ability to drive cars and manage mechanized equipment.
If it is necessary to use during pregnancy, treatment should be carried out under the strict supervision of a doctor.
When an overdose of the drug, bleeding and the development of bleeding are possible. In this situation, it is necessary to cancel the anticoagulant and perform symptomatic therapy.
Refers to prescription drugs.
Store in a dry place, protected from light, out of reach of children, at a temperature not exceeding 30 ° C.
Shelf life of the drug is 5 years from the date of issue. After the expiration date indicated on the package, the drug should not be used.
The average price in pharmacies in Moscow
Wessel Doué F Analogues